These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36418994)

  • 1. Bedaquiline resistance probability to guide treatment decision making for rifampicin-resistant tuberculosis: insights from a qualitative study.
    Tu PHT; Anlay DZ; Dippenaar A; Conceição EC; Loos J; Van Rie A
    BMC Infect Dis; 2022 Nov; 22(1):876. PubMed ID: 36418994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on the resistance of rifampicin-resistant Mycobacterium tuberculosis to anti-tuberculosis drugs in group A].
    Dai XW; Li CY; Wang NH; Chen SS; Tian LL; Zhao YF; Tao LY; Yang XY; Ding BC; He XX
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1110-1117. PubMed ID: 37914422
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
    Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
    BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of bedaquiline resistance probability on treatment decision for rifampicin-resistant TB.
    Trang TPH; Kessels R; Decroo T; Van Rie A
    IJTLD Open; 2024 Sep; 1(9):384-390. PubMed ID: 39301135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary bedaquiline resistance in Karakalpakstan, Uzbekistan.
    Moe S; Rekart ML; Hernandez D; Sholpan A; Ismailov A; Oluya M; Bayniyazova A; Zinaida T; Nargiza P; Gomez-Restrepo C; Sitali N; Sinha A
    Int J Tuberc Lung Dis; 2023 May; 27(5):381-386. PubMed ID: 37143220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study.
    Souleymane MB; Decroo T; Mamadou S; Soumana A; Lawan IM; Gagara-Issoufou A; Adehossi E; Ortuño-Gutiérrez N; Lynen L; Rigouts L; de Jong BC; Van Deun A; Piubello A
    Int Health; 2023 May; 15(3):258-264. PubMed ID: 35420123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the all-oral bedaquiline-containing regimen as treatment for pediatric multidrug/rifampicin-resistant tuberculosis: a multicenter, retrospective, cohort study.
    Sun WW; Yang M; Chen XH; Fan LC; Wu HY; Zhang SJ; Chen Y; Fan L
    Expert Rev Anti Infect Ther; 2024 Apr; 22(4):219-227. PubMed ID: 37982155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of all-oral and injectable-containing, bedaquiline-based long treatment regimen for pre-XDR tuberculosis in Vietnam.
    Nguyen TMP; Nguyen BH; Hoang TTT; Nguyen HA; Vu DH; Nguyen MH; Nguyen BN; Decroo T; Nguyen VN
    Front Pharmacol; 2022; 13():1023704. PubMed ID: 36313324
    [No Abstract]   [Full Text] [Related]  

  • 9. Effectiveness of bedaquiline containing all oral longer regimens in treating multidrug/rifampicin resistant tuberculosis in Pakistan.
    Khan A; Khan AH; Ahmad N; Ghafoor A
    J Infect Public Health; 2024 Sep; 17(9):102522. PubMed ID: 39173557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular determinants of multidrug-resistant tuberculosis in Sierra Leone.
    Blankson HNA; Kamara RF; Barilar I; Andres S; Conteh OS; Dallenga T; Foray L; Maurer F; Kranzer K; Utpatel C; Niemann S
    Microbiol Spectr; 2024 Mar; 12(3):e0240523. PubMed ID: 38289066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT.
    Gao J; Gao M; Du J; Pang Y; Mao G; Lounis N; Bakare N; Jiang Y; Zhan Y; Liu Y; Li L;
    Trials; 2024 Apr; 25(1):227. PubMed ID: 38561815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisation.
    Souleymane MB; Decroo T; Soumana A; Maman Lawan I; Gagara-Issoufou A; Halidou-Moussa S; Ortuño-Gutiérrez N; Adehossi E; Mamadou S; Van Deun A; Piubello A
    Trials; 2022 Dec; 23(1):1011. PubMed ID: 36514153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
    Sarin R; Singla N; Vohra V; Singla R; Puri MM; Munjal S; Khalid UK; Myneedu VP; Kumar Verma A; Mathuria KK
    Indian J Tuberc; 2019 Jan; 66(1):209-213. PubMed ID: 30878071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early mortality during rifampicin-resistant TB treatment.
    Mohr-Holland E; Daniels J; Reuter A; Rodriguez CA; Mitnick C; Kock Y; Cox V; Furin J; Cox H
    Int J Tuberc Lung Dis; 2022 Feb; 26(2):150-157. PubMed ID: 35086627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of line probe assay-based molecular testing on individualized treatment in patients with rifampicin-resistant tuberculosis: data from the prospective INNOVA4TB cohort study in Ukraine.
    Dudnyk A; Hempel M; Lytvyniuk O; Liudkevych H; Matsera V; Nikitchenko T; Blyzniuk S; Molina-Moya B; Preyer R; Domínguez J
    Ther Adv Respir Dis; 2024; 18():17534666241249841. PubMed ID: 38817020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.
    Huerga H; Khan U; Bastard M; Mitnick CD; Lachenal N; Khan PY; Seung KJ; Melikyan N; Ahmed S; Rich ML; Varaine F; Osso E; Rashitov M; Salahuddin N; Salia G; Sánchez E; Serobyan A; Rafi Siddiqui M; Grium Tefera D; Vetushko D; Yeghiazaryan L; Holtzman D; Islam S; Kumsa A; Jacques Leblanc G; Leonovich O; Mamsa S; Manzur-Ul-Alam M; Myint Z; Padayachee S; Franke MF; Hewison C
    Clin Infect Dis; 2022 Oct; 75(8):1307-1314. PubMed ID: 35243494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis.
    Mikiashvili L; Kempker RR; Chakhaia TS; Bablishvili N; Avaliani Z; Lomtadze N; Schechter MC; Kipiani M
    Clin Infect Dis; 2024 Apr; 78(4):1043-1052. PubMed ID: 37962987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.
    Liu Y; Gao J; Du J; Shu W; Wang L; Wang Y; Xue Z; Li L; Xu S; Pang Y
    Int J Infect Dis; 2021 Jan; 102():392-396. PubMed ID: 33130209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
    Chiang CY; Lin CJ
    Indian J Tuberc; 2020 Dec; 67(4S):S16-S22. PubMed ID: 33308663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bedaquiline Resistance and Molecular Characterization of Rifampicin-Resistant
    Tong E; Zhou Y; Liu Z; Zhu Y; Zhang M; Wu K; Pan J; Jiang J
    Infect Drug Resist; 2023; 16():6951-6963. PubMed ID: 37928607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.